



US007829526B2

(12) **United States Patent**
Shichiri

(10) **Patent No.:** **US 7,829,526 B2**
(45) **Date of Patent:** **Nov. 9, 2010**

(54) **CARDIOINHIBITORY/ANTIHYPERTENSIVE NOVEL ENDOGENOUS PHYSIOLOGICALLY ACTIVE PEPTIDE**

WO WO 01/32875 * 5/2001
WO WO 01/32875 A1 5/2001

(75) Inventor: **Masayoshi Shichiri**, Tokyo (JP)

(73) Assignee: **Japan Science and Technology Agency**, Saitama (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 783 days.

(21) Appl. No.: **10/599,479**

(22) PCT Filed: **Apr. 1, 2005**

(86) PCT No.: **PCT/JP2005/006510**

§ 371 (c)(1),
(2), (4) Date: **Dec. 19, 2006**

(87) PCT Pub. No.: **WO2005/095609**

PCT Pub. Date: **Oct. 13, 2005**

(65) **Prior Publication Data**

US 2008/0267871 A1 Oct. 30, 2008

(30) **Foreign Application Priority Data**

Apr. 2, 2004 (JP) 2004-110463

(51) **Int. Cl.**
C07K 14/00 (2006.01)
A61K 49/00 (2006.01)
C07H 21/04 (2006.01)

(52) **U.S. Cl.** **514/2**; 514/13; 530/300;
536/23.1

(58) **Field of Classification Search** 514/2,
514/13; 530/300; 536/23.1
See application file for complete search history.

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

JP 2004-008027 6/2004

OTHER PUBLICATIONS

Masayoshi Shichiri et al., Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities, *Nature Medicine*, Sep. 2003, pp. 1166-1172, vol. 9, No. 9.

Hua Lou and Robert F. Gagel, *Alternative Ribonucleic Acid Processing in Endocrine Systems*, *Endocrine Reviews*, 2001, pp. 205-225, The Endocrine Society, vol. 22, No. 2.

Masayoshi Shichiri, *Salusins*, Jul. 7, 2004, pp. 267-270, vol. 210, No. 4.

Fang Yu et al., *Salusins promote cardiomyocyte growth but does not affect cardiac function in rats*, *Regulatory Peptides*, published online on Aug. 18, 2004, pp. 191-197, No. 122, Elsevier.

Hajime Izumiya et al., *Synthetic Salusins as Cardiac Depressors in Rat*, *Hypertension*, Mar. 2005, pp. 419-425, No. 45, American Heart Association.

International Preliminary Report On Patentability and Written Opinion The International Bureau of WIPO, Oct. 19, 2006, Switzerland corresponding to PCT/JP2005/006510.

* cited by examiner

Primary Examiner—Chih-Min Kam

(74) *Attorney, Agent, or Firm*—Locke Lord Bissell & Liddell LLP

(57) **ABSTRACT**

The present invention is to provide a novel peptide having a potent hypotensive activity by inhibiting cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, or a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient. A search of a genetic data base revealed the presence of a peptide biosynthesized by a processing of unspliced product of TOR2A mRNA. As a result of functional analysis, a peptide hormone exerting a potent bioactivity and expressed abundantly throughout human organs was found. The peptide is hydrophobic with a molecular weight of 2664.02 consisting of 24 amino acids (AIFIFISNTGGKQINQVALEAWRS; SEQ ID NO.: 2) and shows a negative inotropism in rat hearts, as well as a marked systemic hypotensive activity.

5 Claims, 1 Drawing Sheet

Fig. 1





Fig. 2



1

**CARDIOINHIBITORY/ANTIHYPERTENSIVE
NOVEL ENDOGENOUS PHYSIOLOGICALLY
ACTIVE PEPTIDE**

This application is a 371 of PCT/JP2005/006510, filed Apr. 1, 2005, which claims the benefit of foreign application JAPAN 2004-110463, filed Apr. 2, 2004.

TECHNICAL FIELD

The present invention relates to a novel cardioinhibitory/hypotensive endogenous bioactive peptide, a DNA encoding the peptide, an antibody against the peptide, and a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient.

TECHNICAL FIELD

The present inventor previously found salusin- α and salusin- β which are bioactive factors, by a method applying bioinformatics analysis. Salusin- α and salusin- β , related peptides of 28 amino acids (SEQ ID NO: 3), and 20 amino acids (SEQ ID NO: 4), respectively, are biosynthesized by a processing of preprosalusin (PSECO218, HEMBA 1005096, AK075520) which is an alternatively spliced product of Torsin dystoria-family (Torsin family) gene (TOR2A gene) expressed by a frame shift due to deletion of exon 4 (see for example, non-patent document 1). Systemic hemodynamics and aortic vascular effects of a synthesized salusin- α , β on rats were investigated. In other words, synthesized salusin- α and - β were injected intravenously into femoral vein of SD rats (250-300 g) after cannulating femoral artery under pentobarbital anesthesia, to analyze chronological change of blood pressure and heart rates. Moreover, effects of salusin- α and β on vascular tonus were investigated using contracted isolated rat aortic preparation pretreated with phenylephrine.

As a result, both salusin- α and - β induced a rapid hypotensive and bradycardiac effects 1 min after intravenous administration, but the reduced pressure and heart rate returned to a normal level within 10 to 15 min. The hypotensive and bradycardiac effects by salusin- α (1-10 nmol/kg) and salusin- β (0.1-1 nmol/kg) were dose-responsive. The potency of salusin- β was approximately 10-fold greater compared to salusin- α . The hypotensive effects of salusins were not affected by pre-treatment with NO synthase inhibitor, L-NAME. Moreover, studies using isolated preparation of rat aorta did not show any direct effect of salusin- α and - β on intact and endothelium-detached preparations uncontracted or constricted with phenylephrine. In addition to the negative vascular effects, since salusins (α and β), endogenous peptides, induce bradycardia together with a potent hypotensive effect, they are considered to be bioactive peptides with a novel hypotensive mechanism.

Further, it is known that adenosine lowers heart rates (negative chronotropic effect) and lowers impulse transmission via A-V nodes (negative transmission effect) (for example, see patent document 1, non-patent document 2) Further, use of particular adenosine A1 agonist belonging to the class of N6-substituted-5'-(N-substituted) carboxyamidoadenosine for treating impairment of heart rhythm in mammals, and a novel dosage form to practice this use have been proposed (for example, see patent document 2).

Patent document 1: U.S. Pat. No. 4,673,563

Patent document 2: Published Japanese translation of PCT international publication No. 2003-514863

Non-patent document 1: Nat Med 9: 1166-72, 2003

2

Non-patent document 2: Journal of Pharmacology and Experimental Therapeutics 271:1371, 1994

DISCLOSURE OF THE INVENTION

Object to be Solved by the Invention

The object of the present invention is to provide a novel peptide having a potent hypotensive activity by suppressing cardiac contractility, a DNA encoding the peptide, an antibody against the peptide, and a cardioinhibitory/hypotensive agent comprising the peptide as an active ingredient, or the like.

Means to Solve the Object

As mentioned above, the present inventor recently applied bioinformatic analysis of human-secretory protein cDNA library, to identify multifunctional peptides that are estimated to be biosynthesized after alternative splicing and subsequent frame shift, and designated as salusin- α and salusin- β (see non-patent document 1). Although the alternative splicing is evident in many major human organs, the produced mRNA constitutes a portion of the spliced and predominant unspliced product. Therefore, their concentrations in human blood and the specific role of these peptides remain unclear. While searching preprosalusin gene sequence, the present inventor found unspliced TOR2A mRNA and estimated the presence of a putative peptide biosynthesized by a processing, being translated from TOR2A mRNA itself. As a result of functional analyses, the present inventor discovered a peptide hormone with a potent bioactivity that expresses in a larger amount throughout various human organs. This peptide is hydrophobic, with a molecular weight of 2664.02 consisting of 24 amino acids, and shows a negative inotropism in rat hearts, as well as a significant hypotensive activity. The present inventor confirmed that a peptide of high homology, with only one amino acid substituted is expressed in rat and human and shows similar functions.

While the above-mentioned peptide of the present invention is an endogenous hypotensive factor produced in various human organs, similarly to salusin- α and salusin- β , it may be more useful since it is expressed and biosynthesized in a larger amount compared to both salusins. Intravenous administration of this peptide of the present invention into anesthetized rats resulted in a marked lowering of aortic pressure (FIG. 1), reduced heart rates and aortic blood flow. The results revealed this factor to be the most potent endogenous peptide identified thus far showing negative inotropic (FIG. 2) and chronotropic effects. Studies using isolated perfused rat hearts also revealed that the peptide directly acts on heart to potentially reduce cardiac contractility. The present invention has been completed based on these findings.

In other words, the present invention relates to (1) a peptide consisting of any one of the following amino acids: (A) the amino acid sequence shown by SEQ ID No: 2; (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the sequence shown by SEQ ID No: 2, wherein a peptide consisting of the amino acid sequence has a cardioinhibitory activity or hypotensive activity; (C) an amino acid sequence having 60% or more homology with the amino acid sequence shown by SEQ ID No: 2, wherein a peptide consisting of the amino acid sequence has a cardioinhibitory activity or hypotensive activity; (2) a peptide generated from (A) the amino acid sequence shown by SEQ ID No: 2; or (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the sequence

3

shown by SEQ ID No: 2, as a result of further cleavage or modification by a processing enzyme and having a cardioinhibitory activity or hypotensive activity.

Further, the present invention relates to (3) (A) a DNA encoding a peptide consisting of the amino acid sequence shown by SEQ ID No: 2; (B) a DNA encoding a peptide consisting of an amino acid sequence wherein one or a few amino acids are deleted, substituted, or added in the sequence shown by SEQ ID No: 2, and having a cardioinhibitory activity or hypotensive activity; (C) a DNA encoding a peptide consisting of an amino acid sequence having 60% or more homology with the amino acid sequence shown by SEQ ID No: 2, and having a cardioinhibitory activity or hypotensive activity; (D) a DNA consisting of the nucleotide sequence shown by SEQ ID No: 1; (E) a DNA encoding a peptide consisting of a nucleotide sequence wherein one or a few nucleotides are deleted, substituted or added in the shown by SEQ ID No: 1, and having a cardioinhibitory activity or hypotensive activity; (F) a DNA that hybridizes with the nucleotide sequence shown by SEQ ID No: 1 under a stringent condition, and encoding a peptide having a cardioinhibitory activity or hypotensive activity; (4) a DNA generated from (A) the amino acid sequence shown by SEQ ID No: 2; or (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID No: 2, as a result of further cleavage or modification by a processing enzyme and having a cardioinhibitory activity or hypotensive activity.

Further, the present invention relates to (5) a fusion peptide wherein the peptide according to (1) or (2) is bound with a marker protein and/or peptide tag; (6) a recombinant vector comprising the DNA according to (3) wherein the recombinant vector can express the peptide according to (1); (7) a recombinant vector comprising the DNA according to (4), wherein the recombinant vector can express the peptide according to (2); (8) a transformant wherein the recombinant vector according to (6) is introduced, which expresses the peptide according to (1) (9) a transformant wherein the recombinant vector according to (7) is introduced, which expresses the peptide according to (2); (10) an antibody that can recognize specifically the peptide according to (1) or (2); (11) the antibody according to (10) wherein the antibody is a monoclonal antibody; (12) a method for screening a cardioinhibitory factor or hypotensive factor, comprising the steps of administering the peptide according to (1) or (2) and a test substance to a non-human test animal, and measuring/estimating a level of cardioinhibitory activity or hypotensive activity; (13) a method for screening an inhibitor of cardioinhibitory activity or an inhibitor of hypotensive activity, comprising the steps of administering the peptide according to (1) or (2) and a test substance to a non-human test animal, and measuring/estimating a level of cardioinhibitory or hypotensive activity; (14) a cardioinhibitory/hypotensive agent comprising the peptide according to (1) or (2) as an active ingredient; or (15) a method for preventing/treating diseases which requires administration of the cardioinhibitory/hypotensive agent according to (14) via its cardioinhibitory/hypotensive activity.

Effect of the Invention

A peptide of the present invention is a novel endogenous peptide in humans, inhibiting cardiac contractility, and expected to be effective as a hypotensive agent with minimal side-effect. By further investigating the roles of the peptide, future research advance is anticipated for the development of new therapeutic agents, such as β -antagonist mimetics, in the

4

treatment of cardiovascular diseases including angina, and for elucidating the mechanism of cardiac failure/angina.

BEST MODE OF CARRYING OUT THE INVENTION

A peptide of the present invention is not specifically limited as long as it is a peptide consisting of any one of the following amino acids: (A) the amino acid sequence shown by SEQ ID No: 2; (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID No: 2, and having a cardioinhibitory activity or hypotensive activity; or (C) an amino acid sequence having 60% or more homology with the amino acid sequence shown by SEQ ID No: 2, and having a cardioinhibitory activity or hypotensive activity; or a peptide generated from (A) the amino acid sequence shown by SEQ ID No: 2; or (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID No: 2, as a result of further cleavage or modification by a processing enzyme and having a cardioinhibitory activity or hypotensive activity. Further, a DNA of the present invention is not specifically limited as long as it is any one of the following: (A) a DNA encoding a peptide consisting of the amino acid sequence shown by SEQ ID No: 2; (B) a DNA encoding a peptide consisting of an amino acid sequence wherein one or a few amino acids are deleted, substituted, or added in the sequence shown by SEQ ID No: 2, and having a cardioinhibitory activity or hypotensive activity; (C) a DNA encoding a peptide consisting of an amino acid sequence having 60% or more homology with the amino acid sequence shown by SEQ ID No: 2, and having a cardioinhibitory activity or hypotensive activity; (D) a DNA consisting of the nucleotide sequence shown by SEQ ID No: 1; (E) a DNA encoding a peptide consisting of a nucleotide sequence wherein one or a few nucleotides are deleted, substituted or added in the sequence shown by SEQ ID No: 1, and having a cardioinhibitory activity or hypotensive activity; (F) a DNA that hybridizes with the nucleotide sequence shown by SEQ ID No: 1 under a stringent condition, and encoding a peptide having a cardioinhibitory activity or hypotensive activity; or a DNA encoding a peptide consisting of (A) an amino acid sequence shown by SEQ ID No: 2; or (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID No: 2 and having a cardioinhibitory activity or hypotensive activity; generated by a cleavage or modification by a processing enzyme. "A peptide having a cardioinhibitory activity or hypotensive activity" herein mentioned relates to a peptide comprising a negative inotropism/negative chronotropic effect, associated with the inhibition of cardiac contractility, or to a peptide having a hypotensive activity. However, the specific mechanism of action is not specifically limited. Examples of the specific mechanisms include, lowering of aortic pressure, lowering of heart rates/pulse rates, lowering of aortic blood flow rate, lowering of cardiac output, lowering of coronary blood flow and lowering of peripheral blood pressure. However, it is not limited to these examples.

"An amino acid sequence wherein one or a few amino acids are deleted, substituted or added" herein mentioned relates to an amino acid wherein, any number of amino acids, for example, 1 to 10, preferably 1 to 5 amino acids are deleted, substituted or added. Further, "a nucleotide sequence wherein one of a few nucleotides are deleted, substituted or added" mentioned in the above, relates to a nucleotide sequence wherein, any number of nucleotides, for example, 1 to 20,

5

preferably 1 to 15, more preferably 1 to 10, further preferably 1 to 5 nucleotides are deleted, substituted or added. Moreover, as a specific example of an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID No: 2, having a cardioinhibitory activity or a hypotensive activity, an amino acid sequence wherein 4 amino acids at C-terminal end are deleted: (1-20); an amino acid sequence wherein 4 amino acids at N terminal end are deleted (5-24), a potent cardioinhibitory activity or hypotensive activity is maintained. In a sequence wherein 11 amino acids at C-terminal end, and 1 amino acid at N-terminal end are deleted (2-13), even the activity is somewhat decreased, it has been confirmed that the cardioinhibitory activity or hypotensive activity is maintained.

For example, a DNA consisting of a nucleotide sequence wherein one or a few nucleotides are deleted, substituted or added (mutant DNA), can be prepared by any conventional methods, such as chemosynthesis, DNA engineering method, or mutagenesis. Specifically, a mutant DNA can be obtained by introducing a mutation to the DNA consisting of the sequence shown by SEQ ID No: 1 by using a method allowing the DNA to contact and react with an agent as a mutagen, a method irradiating ultraviolet ray or a DNA engineering method. Site-specific mutagenesis, which is one of DNA engineering methods, is useful as it is a method that can introduce a specific mutation to a specific site. The method can be performed according to Molecular Cloning: A laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1989 (hereinafter referred to as "Molecular Cloning 2nd Ed."), Current Protocols in Molecular Biology, Supplement 1-38, John Wiley & Sons (1987-1997). By expressing the mutant DNA with the use of an appropriate expression system, a peptide consisting of an amino acid sequence wherein one or a few amino acids are deleted, substituted or added can be obtained.

In the present invention, "an amino acid sequence having 60% or more homology with the amino acid sequence shown by SEQ ID No: 2" is not specifically limited as long as the homology with the amino acid sequence shown by SEQ ID No: 2 is 60% or more, for example 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, particularly preferably 95% or more, and most preferably 98% or more.

In the present invention, "a nucleotide sequence that hybridizes under a stringent condition" relates to a nucleotide sequence that can be obtained by colony hybridization method, plaque hybridization method, or southern blotting hybridization method, with the use of nucleic acids such as DNA or RNA as a probe. Specifically, a DNA that can be identified by hybridizing at 65° C. in the presence of 0.7 to 1.0 M NaCl, with the use of a filter on which a DNA derived from a colony or a plaque, or a fragment thereof is immobilized, and by washing the filter with a 0.1 to 2-fold SSC solution (one-fold concentration SSC solution is composed of 150 mM sodium chloride and 15 mM sodium citrate) under a condition of 65° C. is exemplified. Hybridization can be performed according to a method described in Molecular Cloning, 2nd Ed. For example, as a DNA that can hybridize under a stringent condition, a DNA having a certain homology with the nucleotide sequence of the DNA used as a probe. A DNA having for example 60% or more, preferably 70% or more, more preferably 80% or more, further preferably 90% or more, particularly preferably 95% or more, and most preferably 98% or more homology can be preferably exemplified.

A method for obtaining or preparing a DNA of the present invention is not specifically limited. A desired DNA can be

6

prepared by isolating the DNA by screening a cDNA library that is expected to contain the DNA with the use of an appropriate probe or primer prepared according to the amino acid sequence or nucleotide sequence information shown by SEQ ID No: 1 or 2 disclosed in the present invention, or by chemosynthesis according to a common procedure.

Specifically, a DNA expressing the peptide of the present invention can be obtained by first preparing a human cDNA library according to a common procedure since cDNA of the present invention derived from human tissue, preparing an appropriate probe specific to the DNA of the present invention from the library according to the sequence information of TOR2A genes, and selecting the desired clone by using the probe. Origins of the above cDNA include various cells or tissues derived from animals including human and rats. Further, isolation of total RNA from these cells or tissues, as well as isolation or purification of mRNA, acquisition of cDNA and cloning thereof, can all be performed according to a common procedure. For example, methods for screening a DNA of the present invention from a cDNA library includes those described in Molecular Cloning, 2nd Ed. The nucleotide sequence of a DNA of the present invention derived from human is exemplified as SEQ ID No: 1, and the nucleotide sequence of a DNA of the present invention derived from rat is exemplified as SEQ ID No: 5. Moreover, the nucleotide sequence of TOR2A gene is exemplified as SEQ ID No: 7.

A mutant DNA or homologous DNA of the present invention comprising the nucleotide sequence shown by any one of the above (B) to (F), can be isolated by using a nucleotide sequence shown by SEQ ID No: 1 or a DNA fragment comprising a part thereof, and screening under a certain condition a homolog of the DNA from other organisms and the like. Further, it can be prepared by a method of preparing a mutant DNA, described in the above.

A method for obtaining/preparing a peptide of the present invention is not specifically limited, and it can be a naturally occurring peptide, chemosynthesized peptide, or a recombinant peptide prepared by DNA recombination technology. When obtaining a naturally occurring peptide, a peptide of the present invention can be obtained by combining appropriate methods for isolating/purifying a peptide from cells or tissues expressing the peptide. When preparing a peptide by chemosynthesis, a peptide of the present invention can be synthesized according to chemosynthesis method such as Fmoc method (fluorenylmethyloxycarbonyl method), tBoc method (t-butyloxycarbonyl method). Moreover, a peptide of the present invention can be synthesized by using various commercial peptide synthesizers. When preparing a peptide by DNA recombination technology, a peptide of the present invention can be prepared by introducing a DNA consisting of the nucleotide sequence encoding the peptide into a suitable expression system.

When preparing a peptide of the present invention by DNA recombination technology, in order to collect and purify the peptides from cell cultures, conventional methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxy apatite chromatography and lectin chromatography can be used, and high performance liquid chromatography is preferably used. Especially, as a column used in affinity chromatography, by using a column bound with an antibody such as monoclonal antibodies against a peptide of the present invention, or when a normal peptide tag is added to the above-mentioned peptide of the present inven-

tion, a column bound with a substance having affinity to the peptide tag, purified materials of these peptides can be obtained.

Furthermore, the peptides of the present invention comprising the human-derived amino acid sequence shown by SEQ ID No: 2, peptides consisting of an amino acid sequence wherein one or a few amino acids are deleted, substituted, or peptides consisting of an amino acid sequence having 60% or more homology with the amino acid sequence shown by SEQ ID No: 2, can be appropriately prepared or obtained by a person skilled in the technique using the information of the nucleotide sequence SEQ ID No: 1 encoding the amino acid sequence, SEQ ID No: 2. For example, it can be isolated by screening under an appropriate condition a homolog of the DNA from an organism other than human, with the use of the sequence SEQ ID No: 1 or a DNA comprising a part thereof, as a probe. Moreover, a peptide encoded by the homolog DNA can be produced by cloning a full-length DNA of the homolog DNA, and subsequently integrating it into an expression vector to express it in an appropriate host. The amino acid sequence of a peptide of the present invention derived from rats is exemplified as SEQ ID No: 6. Further, for reference, the amino acid sequence of TOR2A is exemplified as SEQ ID No: 8.

The above peptide generated from (A) the amino acid sequence shown by SEQ ID No: 2; or (B) an amino acid sequence wherein one or a few amino acids are deleted, substituted or added in the amino acid sequence shown by SEQ ID No: 2, as a result of further cleavage or modification by a processing enzyme and having a cardioinhibitory activity or hypotensive activity, can be obtained easily by synthesizing various peptides including the N-terminal region of the peptide consisting of the amino acid sequence shown by SEQ ID No: 2, and by screening their cardioinhibitory activity or hypotensive activity; or by detecting human serum by using an antibody that recognizes specifically the N-terminal region of the peptide consisting of the amino acid sequence shown by SEQ ID No: 2. Further, a DNA consisting of the sequence encoding the peptide can be easily prepared according to the amino acid sequence information of the peptide.

A fusion peptide of the present invention is not specifically limited as long as a peptide of the present invention is bound with any marker protein and/or peptide tag. A marker protein is not specifically limited if it is conventionally known, including enzymes such as alkaline phosphatase and HRP, Fc region of the antibody, and fluorescent substances such as GFP. Specific examples of peptide tags of the present invention include epitope tags such as HA, FLAG and Myc; affinity tags such as GST, maltose-binding protein, biotinylated peptide and oligohistidine, which are conventionally known peptide tags. The fusion peptides can be prepared by a common procedure, and are useful for purifying a peptide of the present invention using the affinity of Ni-NTA and His tag, detecting a peptide of the present invention, quantifying an antibody against a peptide of the present invention, and also as a research reagent for the present invention.

A recombinant vector of the present invention is not specifically limited as long as it comprises a DNA of the present invention mentioned above and can express a peptide of the present invention mentioned above. A recombinant vector of the present invention can be constructed by integrating appropriately a DNA of the present invention into, for example, an expression vector for animal cell expression. An expression vector should preferably be self-replicable in host cells, or could be recombined into chromosomes of host cells. Further, an expression vector comprising a regulatory sequence such as a promoter, enhancer or terminator, at a suitable position

where a DNA of the present invention can be expressed, can be preferably used. Additionally, an expression system could be any system as long as it can express a peptide of the present invention in host cells, and include the following: expression systems derived from chromosome, episome and virus, for example, vectors derived from bacterial plasmid, yeast plasmid, papovavirus such as SV40, vaccinia virus, adenovirus, fowl poxvirus, pseudorabies virus or retrovirus; vectors derived from bacteriophage, transposon, or from a combination thereof, for example those derived from genetic elements of plasmid and bacteriophage such as cosmids and phagemids.

A transformant of the present invention is not specifically limited as long as it is introduced a recombinant vector of the present invention mentioned above and can express a peptide of the present invention mentioned above. Examples include transgenic yeast, transgenic plants (cells, tissues, individuals), transgenic bacteria, transgenic animals (cells, tissues, individuals), while transgenic animal cells are preferable. Examples of animal host cells include Namalva cells, COS1 cells, COS7 cells and CHO cells. As a method for introducing a recombinant vector into animal cells, for example, electroporation method, calcium phosphate method and lipofection method can be used.

As to an antibody specifically recognizing a peptide of the present invention, an antibody binding specifically to a peptide of the present invention is preferable. Examples of such antibodies include immune-specific antibodies such as monoclonal antibodies, polyclonal antibodies, chimeric antibodies, single-stranded antibodies and humanized antibodies. These can be prepared by a common procedure by using a peptide of the present invention as an antigen, while among these, monoclonal antibodies are preferable for its specificity, and polyclonal antibodies are preferable for its sensitivity. Antibodies binding specifically to a peptide of the present invention such as monoclonal antibodies and polyclonal antibodies are useful for elucidating a pathophysiological value of a peptide of the present invention in various diseases, diagnosing diseases caused by a mutation or deletion of a peptide of the present invention, or revealing a molecular mechanism of a peptide of the present invention.

An antibody against a peptide of the present invention is produced by administering a fragment comprising the peptide or epitope to an animal (preferably other than human) by using conventional protocols. For example, when preparing a monoclonal antibody, any method including hybridoma method (Nature 256, 495-497, 1975); trioma method, human B cell hybridoma method (Immunology Today 4, 72, 1983), and EBV-hybridoma method (MONOCLONAL ANTIBODIES AND CANCER THERAPY, pp. 77-96, Alan R. Liss, Inc., 1985) can be used. In the following, a method for preparing a monoclonal antibody binding specifically to a peptide of the present invention derived from a mouse, by taking a peptide derived from human as an example of a peptide of the present invention, will be explained.

A monoclonal antibody of the present invention can be produced by culturing the monoclonal antibody-producing hybridoma by a common procedure, in vivo or in vitro. For example, in an in vivo system, it can be obtained by culturing in a peritoneal cavity of rodents, preferably mouse or rat, and in an in vitro system, it can be obtained by culturing in a medium for culturing animal cells. As a medium for culturing hybridomas in an in vitro system, a cell culture medium such as RPMI1640 or MEM comprising antibiotics such as streptomycin or penicillin can be exemplified.

As a monoclonal antibody-generating hybridoma of the present invention mentioned in the above, a hybridoma gen-

erating a monoclonal antibody of the present invention can be produced by immunizing a BALB/c mouse with a peptide of the present invention obtained from human or rat, by performing cell fusion of spleen cells of the immunized mouse and mouse NS-1 cells (ATCC TIB-18) according to a common procedure and screening by immunofluorescent staining patterns. Further, a method for separating/purifying the monoclonal antibody can be any method that is used generally for purifying peptides or proteins, and liquid chromatography such as affinity chromatography can be specifically exemplified.

In order to produce a single-strand antibody against a peptide of the present invention mentioned in the above of the present invention, a method for preparing a single-strand antibody (U.S. Pat. No. 4,946,778) can be applied. Further, in order to express a humanized antibody, it is possible to use a transgenic mouse or other mammals, to separate/isolate clones expressing a peptide of the present invention, or to purify a peptide of the present invention by affinity chromatography, by using the above antibody. An antibody against a peptide of the present invention is useful to elucidate the molecular mechanism of a peptide of the present invention.

Further, functional analysis of a peptide of the present invention can be advantageously performed by using fluorescent substances such as FITC (Fluorescein isothiocyanate) or tetramethylrhodamine isocyanate, radioisotopes such as ^{125}I , ^{32}P , ^{14}C , ^{35}S , or ^3H , or those labeled with enzymes such as alkaline phosphatase, peroxidase, β -galactosidase or phycoerythrin, or fusion proteins fused with fluorescent luminescent proteins such as Green fluorescent protein (GFP). Furthermore, as a method of immunological measurement by using an antibody of the present invention, RIA method, ELISA method, fluorescent antibody method, plaque method, spot method, hemagglutination reaction method, or Ouchterlony method can be exemplified.

As a screening method of the present invention, it is not specifically limited as long as it is designed to obtain cardioinhibitory or hypotensive factors or inhibitors of cardioinhibitory or hypotensive activity, comprising the steps of administering a peptide of the present invention derived from human or rats to a non-human test animal model such as rat or mouse with a test substance, and measuring/estimating a level of cardioinhibitory activity or hypotensive activity. Specifically, cardioinhibitory factors or hypotensive factors, or inhibitors of cardioinhibitory or hypotensive activity can be screened by administering a test substance orally or parenterally, before or after, or at the same time of administering a peptide of the present invention intravenously to a non-human test animal such as rats or mice, measuring a level of cardioinhibitory activity such as lowering of blood pressure, aortic pressure, pulse rates, or aortic blood flow rate, and comparing/estimating with a measurement level of a control without being administered a test substance. Examples of the above test substances include natural products such as substances extracted from animals/plants or microorganisms, compounds obtained by chemosynthesis, various bioactive peptides or proteins, or various hypotensive agents or hypertensive agents which are conventionally known as well as various adjuvants. A substance promoting cardioinhibitory activity obtained by a screening method of the present invention is highly possible to be useful as a hypotensive agent when it is used alone or simultaneously with a peptide of the present invention. Further, an inhibitor of cardioinhibitory activity is highly possible to be useful as a cardiotoxic or hypertensive agent when it is used alone or simultaneously with a peptide of the present invention. Moreover, these sub-

stances promoting or inhibiting cardioinhibitory activity are useful for studying the action mechanism of cardioinhibitory/hypotensive activity in vivo.

A cardioinhibitory/hypotensive agent of the present invention is not specifically limited as long as it comprises a peptide of the present invention as an active ingredient. Further, a method for preventing/treating diseases that necessitate cardioinhibitory or hypotensive activity of the present invention is not specifically limited as long as it is a method comprising the step of administering a cardioinhibitory/hypotensive agent of the present invention to a patient necessitating cardioinhibitory activity or hypotensive activity. "A cardioinhibitory activity or hypotensive activity" herein mentioned relates to an activity inhibiting cardiac function, including lowering of blood pressure, lowering of aortic pressure, lowering of pulse rates and lowering of aortic blood flow rate. A cardioinhibitory/hypotensive agent of the present invention can be used advantageously for preventing or treating diseases including hypertension, angina, cardiac failure, arrhythmia and hypertrophic cardiomyopathy, as it has a cardioinhibitory activity.

When using such cardioinhibitory/hypotensive agent as a drug, various prescribed compounds such as pharmaceutically acceptable normal carrier, bonding agent, stabilizing agent, excipient, diluent, pH buffer agent, disintegrator, solubilizer, dissolving adjuvant, and isotonic agents can be added. The agent can be administered orally or parenterally. In other words, it can be administered orally in a dosage form which is generally used, for example in form of powder, granule, capsule, syrup, suspension, or parenterally for example in form of solution, emulsion, suspension by an injection. Moreover, it can also be administered in nostril in form of spray. Parenteral administration is preferable. In administering parenterally, aqueous solvents such as distilled water and saline, dissolving adjuvants such as sodium salicylate, isotonic agents such as sodium chloride, glycerin, D-mannitol, stabilizing agents such as human serum albumin, preservatives such as methyl paraben, local anesthetics such as benzyl alcohol, can be compounded.

The dosage of a cardioinhibitory/hypotensive agent of the present invention can be selected appropriately depending on types of diseases, body weight or age of the patient, reagent form, symptoms, etc. For example, when administering to an adult, it is preferable to administer a peptide of the present invention or a pharmaceutically acceptable salt thereof which is an active ingredient, in an amount of about 0.01 to 100 nmol/kg, preferably 0.05 to 30 nmol/kg, more preferably 0.1 to 10 nmol/kg per dosage, and it is preferable to administer this amount 1 to 3 times a day. When administering parenterally a cardioinhibitory/hypotensive agent of the present invention, it can be administered for example, intravenously, subcutaneously, intramuscularly, in a cavitas medullaris, or mucosally, while intravenous or subcutaneous administration is preferable.

In the following, the present invention will be explained more specifically by referring to the Examples, while the technical scope of the present invention is not limited to these exemplifications.

EXAMPLE 1

Preparation of a Peptide of the Present Invention

The peptide of the present invention consisting of the amino acid sequence (AIFIFISNTGGKQINQVALEAWRS) shown by SEQ ID No:2 was found as follows. When salusin was discovered, it was already expected that a preprosalusin,

11

a precursor of salusin, was generated as a result of an alternative splicing and deletion of exon 4' of a TOR2A gene which consists of 5 exons as evident from a GenBank registered clone (AL162426 Human DNA sequence from clone RP11-56D16 on chromosome 9, complete sequence, April 2001; Length=163338). The TOR2A gene is widely expressed throughout various human organs. A small portion of the transcript becomes spliced into preprosalusin while great majority is expressed as TOR2A mRNA except that in vascular endothelial cells and vascular smooth muscle cells preprosalusin is abundantly expressed. Investigation of an amino acid sequence translated from TOR2A mRNA revealed a sequence predicted to be biosynthesized by pro-hormone convertase, or carboxypeptidase E. Thus, a full-length TOR2A cDNA sequence was cloned by PCR, sub-cloned into pTarget vector (Promega), introduced into cultured vascular endothelial cells to perform a gene expression experiment. A hypotensive activity secreted in the culture supernatant was confirmed in an in vivo experimental system using rats as mentioned above. Fractionation of the hypotensive activity by gel filtration chromatography corresponded to the results of molecular weight fractionation of the peptide shown by SEQ ID No: 2.

Meanwhile, a peptide of the present invention consisting of the amino acid sequence shown by SEQ ID No: 2 determined in Example 1, was synthesized with the use of a peptide synthesizer (Shimadzu, PSSM-8), and tested in the following experiment. SD rats weighing 400 to 525 g were used as test animals.

EXAMPLE 2

Effect of a Synthesized Peptide of the Present Invention on Intact-Rats

SD rats were anesthetized by intraperitoneal pentobarbital sodium (50 mg/kg), and a synthesized peptide was administered intravenously via a catheter placed in the femoral artery. Heart rates and blood pressure were measured according to a method described previously (Nat Med 9: 1166-72, 2003) with the use of an electromagnetic flowmeter (MFV-1100, Nihon Koden). Further, a flowmeter was attached to the

12

abdominal aorta, and aortic flow was measured according to the above method described previously. Synthetic peptides (10 nmol/kg) were administered intravenously over a period of 15 seconds or more, and systolic pressure (SP), diastolic pressure (DP) mean aortic pressure (MAP), heart rate (HR) were measured. Results of hypotensive effects are shown in FIG. 1. A hypotensive effect of a synthetic peptide of the present invention was observed.

EXAMPLE 3

Effect of a Synthetic Peptide of the Present Invention on Isolated Hearts

Isolated heart working model was used for estimating direct effect on cardiac muscle, according to a method described previously (Nat Med 9:1169-72, 2003). A heart isolated from a rat was set on an isolated heart perfusion apparatus (Primetech Corporation, IPH-W2) which was perfused with a Krebs Henseleit Buffer at 37° C., and stabilized. Subsequently, synthetic peptides were administered (10⁻⁸ mol/l). Then, HR, SP, DP, MAP and aortic flow (AF) were measured over a period of 15 min. Coronary flow (CF) was measured by collecting coronary sinus effluent before and at 5 and 10 min after administering the peptide agent. Based on the obtained data, cardiac output (CO) was calculated by adding AF and CF, whereas stroke volume (SV) was obtained by dividing CO by HR, and then normalized by the heart volume of each rat. Results of coronary flow are shown in FIG. 2. As a result, an effect of lowering coronary flow of a synthetic peptide of the present invention was observed.

BRIEF DESCRIPTION OF DRAWINGS

[FIG. 1]

It is a figure showing a hypotensive effect of a synthetic peptide of the present invention in intact-rats.

[FIG. 2]

It is a figure showing a time course of change of stroke volume of isolated, perfused rat hearts by a synthetic peptide of the present invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 72

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

gccatcttca tcttcatcag caacacgggt ggcaagcaga tcaaccaggt ggcattggag 60

gcgtggcgca gc 72

<210> SEQ ID NO 2

<211> LENGTH: 24

<212> TYPE: PRT

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

Ala Ile Phe Ile Phe Ile Ser Asn Thr Gly Gly Lys Gln Ile Asn Gln
1 5 10 15

-continued

Val Ala Leu Glu Ala Trp Arg Ser
20

<210> SEQ ID NO 3
<211> LENGTH: 28
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: salusin-alpha

<400> SEQUENCE: 3

Ser Gly Ala Leu Pro Pro Ala Pro Ala Ala Pro Arg Pro Ala Leu Arg
1 5 10 15

Ala Gln Arg Ala Gly Pro Ala Gly Pro Gly Ala Lys
20 25

<210> SEQ ID NO 4
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: salusin-beta

<400> SEQUENCE: 4

Ala Ile Phe Ile Phe Ile Arg Trp Leu Leu Lys Leu Gly His His Gly
1 5 10 15

Arg Ala Pro Pro
20

<210> SEQ ID NO 5
<211> LENGTH: 72
<212> TYPE: DNA
<213> ORGANISM: Rat

<400> SEQUENCE: 5

gccattttca tctttatcag caatactgga ggtgagcaga tcaaccaggt ggccctggag 60

gcatggcgca gc 72

<210> SEQ ID NO 6
<211> LENGTH: 24
<212> TYPE: PRT
<213> ORGANISM: Rat

<400> SEQUENCE: 6

Ala Ile Phe Ile Phe Ile Ser Asn Thr Gly Gly Glu Gln Ile Asn Gln
1 5 10 15

Val Ala Leu Glu Ala Trp Arg Ser
20

<210> SEQ ID NO 7
<211> LENGTH: 1527
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 7

gcctctgacc gaaatcgggc ctcaaccgga tggcgggtggc gaggcacggc taccggccct 60

ggggctcgat cctcgggctg ctcgggctgg ccttggtctc cgccgcgcgc tgggacgtgg 120

cttctctgcg ctgcaccttc ggctcgttct gcgaatgcga cttctggccc gacttgccgg 180

gtctggaatg tgacctggct caacacctgg ctggccagca tttggccaag gccttggtgg 240

tgaagtcaact gaaggccttt gtacaggacc cagccccag caagcgttg gtcctttccc 300

360 tgcacggctg gacagggcaccc gggaaagtccct acgttagctc cctgctggca cagcatctct
 420 tccggatgg cctctcggagc cctcaagctc atccatctcc cctcatctcc catctccacc
 480 atccagccgg cactgagccag tacaaagagg agctcaagag ctggtctcag gggaaacctca
 540 ctgctgtgtg ccgatccctt tccctctcg atgagatggaa caagctgtgct cctggcctga
 600 tggaaagtccct gacggccctt cctgggtctg gtatggggacc aactatccgca
 660 aagccatctt catcttatcc agcaatctg gtggtcagca gatcaaccag gtggtccttg
 720 aagcctggccg cagccacacagg gacagggagaa aatccagctt acaaggaggtg gagccagtaa
 780 tctcccgagg cttgatggac aacctccaac atggtctctg gcggtctctg atcatggagg
 840 agcaacctgt ggaagctgtg gtgccccctc tcccgctcca gggcatctca ctgccccact
 900 ggtactcaaa tgaagctggct cagltgggccc tggagccccag cgagagaggtg gtccagggccg
 960 tggtagcaag caccacctac tccctggagg tagaacagct ctctctccc aatgctgca
 1020 agcaagtgcc cctccgacct accatcttccc tctgagagagc ccaggtgtgca tgcctgctcc
 1080 cctctgcccc tcagagcaaaa cacgaaaggc ctgggtgtgct cctggaagaa atcttctca
 1140 agctgtgttg caagltgggac ccagagccaca atgttaagat gaagaaagt gtgtggccagg
 1200 ccaaggaagaa aaggtcttaga agcatcttctg ctaagaaact cctgggtacc ccgcaacctc
 1260 acagcgtgac catgccccctg cagtcttagc cttagccttc tcaatgtgaa cggcaactca
 1320 gggacgaagg cctcctggctg cttccagctg gggactctta ctgcatctcc ttgtctgct
 1380 ccttccccag accctcagccc acagactgtg gctggacccca gcaatccagc taggccccggc
 1440 tagcaccctca caggtcccc aaatgggaag actcaagcta ctacatgggc ctgaattca
 1500 aagtttcaa tttgtcaaa gagaacagag attaataaa cttagcttg gtatagaaa
 1527 aaaaaaaaaaaaaaaaaa aaaaaa

<210> SEQ ID NO 8
 <211> LENGTH: 321
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens
 <400> SEQUENCE: 8

1 Met Ala Ala Thr Arg Gly Cys Arg Pro Trp Gly Ser Leu Leu Gly
 5
 20 Leu Leu Gly Leu Val Ser Ala Ala Ala Trp Asp Leu Ala Ser
 25
 35 Leu Arg Cys Thr Leu Gly Ala Phe Cys Gln Cys Asp Phe Arg Pro Asp
 40
 45 Leu Pro Gly Leu Gln Cys Asp Leu Ala Gln His Leu Ala Gly Gln His
 50
 55 Leu Ala Lys Ala Leu Val Val Lys Ala Leu Lys Ala Phe Val Arg Asp
 65
 70
 75
 80
 85 Pro Ala Pro Thr Lys Pro Leu Val Leu Ser Leu His Gly Trp Thr Gly
 90
 95
 100
 105
 110
 115 Gly Gly Leu Arg Ser Pro Arg Val His His Phe Ser Pro Val Leu His
 120
 125
 130
 135
 140
 145
 150
 155
 160
 165
 170
 175
 180
 185
 190
 195
 200
 205
 210
 215
 220
 225
 230
 235
 240
 245
 250
 255
 260
 265
 270
 275
 280
 285
 290
 295
 300
 305
 310
 315
 320
 325
 330
 335
 340
 345
 350
 355
 360
 365
 370
 375
 380
 385
 390
 395
 400
 405
 410
 415
 420
 425
 430
 435
 440
 445
 450
 455
 460
 465
 470
 475
 480
 485
 490
 495
 500
 505
 510
 515
 520
 525
 530
 535
 540
 545
 550
 555
 560
 565
 570
 575
 580
 585
 590
 595
 600
 605
 610
 615
 620
 625
 630
 635
 640
 645
 650
 655
 660
 665
 670
 675
 680
 685
 690
 695
 700
 705
 710
 715
 720
 725
 730
 735
 740
 745
 750
 755
 760
 765
 770
 775
 780
 785
 790
 795
 800
 805
 810
 815
 820
 825
 830
 835
 840
 845
 850
 855
 860
 865
 870
 875
 880
 885
 890
 895
 900
 905
 910
 915
 920
 925
 930
 935
 940
 945
 950
 955
 960
 965
 970
 975
 980
 985
 990
 995
 1000
 1005
 1010
 1015
 1020
 1025
 1030
 1035
 1040
 1045
 1050
 1055
 1060
 1065
 1070
 1075
 1080
 1085
 1090
 1095
 1100
 1105
 1110
 1115
 1120
 1125
 1130
 1135
 1140
 1145
 1150
 1155
 1160
 1165
 1170
 1175
 1180
 1185
 1190
 1195
 1200
 1205
 1210
 1215
 1220
 1225
 1230
 1235
 1240
 1245
 1250
 1255
 1260
 1265
 1270
 1275
 1280
 1285
 1290
 1295
 1300
 1305
 1310
 1315
 1320
 1325
 1330
 1335
 1340
 1345
 1350
 1355
 1360
 1365
 1370
 1375
 1380
 1385
 1390
 1395
 1400
 1405
 1410
 1415
 1420
 1425
 1430
 1435
 1440
 1445
 1450
 1455
 1460
 1465
 1470
 1475
 1480
 1485
 1490
 1495
 1500
 1505
 1510
 1515
 1520
 1525
 1530
 1535
 1540
 1545
 1550
 1555
 1560
 1565
 1570
 1575
 1580
 1585
 1590
 1595
 1600
 1605
 1610
 1615
 1620
 1625
 1630
 1635
 1640
 1645
 1650
 1655
 1660
 1665
 1670
 1675
 1680
 1685
 1690
 1695
 1700
 1705
 1710
 1715
 1720
 1725
 1730
 1735
 1740
 1745
 1750
 1755
 1760
 1765
 1770
 1775
 1780
 1785
 1790
 1795
 1800
 1805
 1810
 1815
 1820
 1825
 1830
 1835
 1840
 1845
 1850
 1855
 1860
 1865
 1870
 1875
 1880
 1885
 1890
 1895
 1900
 1905
 1910
 1915
 1920
 1925
 1930
 1935
 1940
 1945
 1950
 1955
 1960
 1965
 1970
 1975
 1980
 1985
 1990
 1995
 2000
 2005
 2010
 2015
 2020
 2025
 2030
 2035
 2040
 2045
 2050
 2055
 2060
 2065
 2070
 2075
 2080
 2085
 2090
 2095
 2100
 2105
 2110
 2115
 2120
 2125
 2130
 2135
 2140
 2145
 2150
 2155
 2160
 2165
 2170
 2175
 2180
 2185
 2190
 2195
 2200
 2205
 2210
 2215
 2220
 2225
 2230
 2235
 2240
 2245
 2250
 2255
 2260
 2265
 2270
 2275
 2280
 2285
 2290
 2295
 2300
 2305
 2310
 2315
 2320
 2325
 2330
 2335
 2340
 2345
 2350
 2355
 2360
 2365
 2370
 2375
 2380
 2385
 2390
 2395
 2400
 2405
 2410
 2415
 2420
 2425
 2430
 2435
 2440
 2445
 2450
 2455
 2460
 2465
 2470
 2475
 2480
 2485
 2490
 2495
 2500
 2505
 2510
 2515
 2520
 2525
 2530
 2535
 2540
 2545
 2550
 2555
 2560
 2565
 2570
 2575
 2580
 2585
 2590
 2595
 2600
 2605
 2610
 2615
 2620
 2625
 2630
 2635
 2640
 2645
 2650
 2655
 2660
 2665
 2670
 2675
 2680
 2685
 2690
 2695
 2700
 2705
 2710
 2715
 2720
 2725
 2730
 2735
 2740
 2745
 2750
 2755
 2760
 2765
 2770
 2775
 2780
 2785
 2790
 2795
 2800
 2805
 2810
 2815
 2820
 2825
 2830
 2835
 2840
 2845
 2850
 2855
 2860
 2865
 2870
 2875
 2880
 2885
 2890
 2895
 2900
 2905
 2910
 2915
 2920
 2925
 2930
 2935
 2940
 2945
 2950
 2955
 2960
 2965
 2970
 2975
 2980
 2985
 2990
 2995
 3000
 3005
 3010
 3015
 3020
 3025
 3030
 3035
 3040
 3045
 3050
 3055
 3060
 3065
 3070
 3075
 3080
 3085
 3090
 3095
 3100
 3105
 3110
 3115
 3120
 3125
 3130
 3135
 3140
 3145
 3150
 3155
 3160
 3165
 3170
 3175
 3180
 3185
 3190
 3195
 3200
 3205
 3210
 3215
 3220
 3225
 3230
 3235
 3240
 3245
 3250
 3255
 3260
 3265
 3270
 3275
 3280
 3285
 3290
 3295
 3300
 3305
 3310
 3315
 3320
 3325
 3330
 3335
 3340
 3345
 3350
 3355
 3360
 3365
 3370
 3375
 3380
 3385
 3390
 3395
 3400
 3405
 3410
 3415
 3420
 3425
 3430
 3435
 3440
 3445
 3450
 3455
 3460
 3465
 3470
 3475
 3480
 3485
 3490
 3495
 3500
 3505
 3510
 3515
 3520
 3525
 3530
 3535
 3540
 3545
 3550
 3555
 3560
 3565
 3570
 3575
 3580
 3585
 3590
 3595
 3600
 3605
 3610
 3615
 3620
 3625
 3630
 3635
 3640
 3645
 3650
 3655
 3660
 3665
 3670
 3675
 3680
 3685
 3690
 3695
 3700
 3705
 3710
 3715
 3720
 3725
 3730
 3735
 3740
 3745
 3750
 3755
 3760
 3765
 3770
 3775
 3780
 3785
 3790
 3795
 3800
 3805
 3810
 3815
 3820
 3825
 3830
 3835
 3840
 3845
 3850
 3855
 3860
 3865
 3870
 3875
 3880
 3885
 3890
 3895
 3900
 3905
 3910
 3915
 3920
 3925
 3930
 3935
 3940
 3945
 3950
 3955
 3960
 3965
 3970
 3975
 3980
 3985
 3990
 3995
 4000
 4005
 4010
 4015
 4020
 4025
 4030
 4035
 4040
 4045
 4050
 4055
 4060
 4065
 4070
 4075
 4080
 4085
 4090
 4095
 4100
 4105
 4110
 4115
 4120
 4125
 4130
 4135
 4140
 4145
 4150
 4155
 4160
 4165
 4170
 4175
 4180
 4185
 4190
 4195
 4200
 4205
 4210
 4215
 4220
 4225
 4230
 4235
 4240
 4245
 4250
 4255
 4260
 4265
 4270
 4275
 4280
 4285
 4290
 4295
 4300
 4305
 4310
 4315
 4320
 4325
 4330
 4335
 4340
 4345
 4350
 4355
 4360
 4365
 4370
 4375
 4380
 4385
 4390
 4395
 4400
 4405
 4410
 4415
 4420
 4425
 4430
 4435
 4440
 4445
 4450
 4455
 4460
 4465
 4470
 4475
 4480
 4485
 4490
 4495
 4500
 4505
 4510
 4515
 4520
 4525
 4530
 4535
 4540
 4545
 4550
 4555
 4560
 4565
 4570
 4575
 4580
 4585
 4590
 4595
 4600
 4605
 4610
 4615
 4620
 4625
 4630
 4635
 4640
 4645
 4650
 4655
 4660
 4665
 4670
 4675
 4680
 4685
 4690
 4695
 4700
 4705
 4710
 4715
 4720
 4725
 4730
 4735
 4740
 4745
 4750
 4755
 4760
 4765
 4770
 4775
 4780
 4785
 4790
 4795
 4800
 4805
 4810
 4815
 4820
 4825
 4830
 4835
 4840
 4845
 4850
 4855
 4860
 4865
 4870
 4875
 4880
 4885
 4890
 4895
 4900
 4905
 4910
 4915
 4920
 4925
 4930
 4935
 4940
 4945
 4950
 4955
 4960
 4965
 4970
 4975
 4980
 4985
 4990
 4995
 5000
 5005
 5010
 5015
 5020
 5025
 5030
 5035
 5040
 5045
 5050
 5055
 5060
 5065
 5070
 5075
 5080
 5085
 5090
 5095
 5100
 5105
 5110
 5115
 5120
 5125
 5130
 5135
 5140
 5145
 5150
 5155
 5160
 5165
 5170
 5175
 5180
 5185
 5190
 5195
 5200
 5205
 5210
 5215
 5220
 5225
 5230
 5235
 5240
 5245
 5250
 5255
 5260
 5265
 5270
 5275
 5280
 5285
 5290
 5295
 5300
 5305
 5310
 5315
 5320
 5325
 5330
 5335
 5340
 5345
 5350
 5355
 5360
 5365
 5370
 5375
 5380
 5385
 5390
 5395
 5400
 5405
 5410
 5415
 5420
 5425
 5430
 5435
 5440
 5445
 5450
 5455
 5460
 5465
 5470
 5475
 5480
 5485
 5490
 5495
 5500
 5505
 5510
 5515
 5520
 5525
 5530
 5535
 5540
 5545
 5550
 5555
 5560
 5565
 5570
 5575
 5580
 5585
 5590
 5595
 5600
 5605
 5610
 5615
 5620
 5625
 5630
 5635
 5640
 5645
 5650
 5655
 5660
 5665
 5670
 5675
 5680
 5685
 5690
 5695
 5700
 5705
 5710
 5715
 5720
 5725
 5730
 5735
 5740
 5745
 5750
 5755
 5760
 5765
 5770
 5775
 5780
 5785
 5790
 5795
 5800
 5805
 5810
 5815
 5820
 5825
 5830
 5835
 5840
 5845
 5850
 5855
 5860
 5865
 5870
 5875
 5880
 5885
 5890
 5895
 5900
 5905
 5910
 5915
 5920
 5925
 5930
 5935
 5940
 5945
 5950
 5955
 5960
 5965
 5970
 5975
 5980
 5985
 5990
 5995
 6000
 6005
 6010
 6015
 6020
 6025
 6030
 6035
 6040
 6045
 6050
 6055
 6060
 6065
 6070
 6075
 6080
 6085
 6090
 6095
 6100
 6105
 6110
 6115
 6120
 6125
 6130
 6135
 6140
 6145
 6150
 6155
 6160
 6165
 6170
 6175
 6180
 6185
 6190
 6195
 6200
 6205
 6210
 6215
 6220
 6225
 6230
 6235
 6240
 6245
 6250
 6255
 6260
 6265
 6270
 6275
 6280
 6285
 6290
 6295
 6300
 6305
 6310
 6315
 6320
 6325
 6330
 6335
 6340
 6345
 6350
 6355
 6360
 6365
 6370
 63

